⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 6, 2013Gut

Tracking the microbiome functionality: focus on Propionibacterium species

Benoît Foligné Jérôme Breton Denis D.G. Mater Gwénaël Jan

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

absent

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Foligné et al. (2013) studied this question.

synapsesocial.com/papers/6a910c292684f6cf7b7a7834 https://doi.org/10.1136/gutjnl-2012-304393

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese womenRCT · 2012 · 827 citations
2Role of the intestinal microbiome in health and disease: from correlation to causationReview · 2012 · 440 citations
3Contribution of Surface β-Glucan Polysaccharide to Physicochemical and Immunomodulatory Properties of Propionibacterium freudenreichiiOriginal Research · 2012 · 38 citations
4Sodium oligomannate remodels gut redox adaptation and promotes microbiota-derived indole-3-propionic acid production to alleviate Alzheimer’s diseaseGut · Fri,
5WTAP resists cholestatic liver injury by m 6 A-IGF2BP1-dependent regulation of the nuclear receptor FXRGut · Fri,

More from Gut

Multisite metastatic atlas of gastric cancer identifies C/EBPβ as a regulator promoting liver metastasisTue,
Burden of liver fibrosis and steatosis coexisting with hepatitis B or C infection in China: a population-based study from the 2020 National Serological SurveyMon,
Prospective study of phosphatidylethanol (PEth) as a diagnostic biomarker for identifying alcohol use disorder (AUD) among participants at risk for steatotic liver diseaseThu,
Microbiota-host genetic interactions modulate MASLD risk in PNPLA3 I148M carriers via ceramides and are reversible by targeted microbial interventionsMon,
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experienceThu,